Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Arenavirus entry inhibitor from Kineta shows preclinical efficacy

May 3, 2016

Further trials planned after phase Ia study of cyclopropavir in healthy subjects

May 3, 2016

Cempra completes rolling NDA submissions for solithromycin in CABP

May 2, 2016

Avibactam/ceftazidime gets positive opinion from CHMP

May 2, 2016

Interim results reported from CyTuVax's phase I study of hepatitis B vaccine

May 2, 2016

Arrowhead Pharmaceuticals files for approval of phase I/II study of ARC-521 in New Zealand

April 29, 2016

Kineta divulges antivirals

April 29, 2016

Janssen submits NDA to FDA seeking approval of mebendazole chewable tablet

April 29, 2016

NVR-3-778 well tolerated and reduces HBV DNA in phase Ib trial

April 29, 2016

Laninamivir octanoate effective and well tolerated as post-exposure prophylaxis for influenza

April 29, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...